Cannabidiol
Approved · FDA / EMAAlso known as (-)-trans-cannabidiol, .DELTA.1(2)-TRANS-CANNABIDIOL, CBD, CBD-A+4 more
(-)-trans-cannabidiol, .DELTA.1(2)-TRANS-CANNABIDIOL, CBD, CBD-A, Epidiolex, cannabidiol (CBD), (-)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol, (1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol.
Recent clinical, regulatory, research and industry developments relating to this drug.
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Label change: CANNABIDIOL (NDA210365)
Label change: CANNABIDIOL (NDA210365)
Label change: CANNABIDIOL (NDA210365)
Label change: CANNABIDIOL (NDA210365)
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical Review.
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients… Show full indicationShow less
Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Reducing Pain and Opioid Use With CBD
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Basic & clinical pharmacology & toxicology1
- Behavioural neurology1
- Pharmacology1
- Pharmacopsychiatry1
- Bhushan B1
- Chanchal DK1
- Coimbra NC1
- Dammann I1
- de Fátima Dos Santos Sampaio M1
- de Paiva YB1
- Kumar G1
- Kumar S1
- Behavioural Neurosciences Institute (INeC)1
- Brain and Mind Centre1
- Center for Agropastoralism Sciences and Technology (CCTA)1
- Central Institute of Mental Health1
- Dr. Bhimrao Ambedkar University1
- Glocal School of Pharmacy1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Cannabidiol in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.